Evidence map›Paper›PMID 28133688›Full record

ArticleSaudi medical journal2017

Hormone receptor status and survival of medullary breast cancer patients. A Turkish cohort.

Asude Aksoy, Hatice Odabas, Serap Kaya, Oktay Bozkurt, Mustafa Degirmenci, Turkan O Topcu, Aydin Aytekin, Erkan Arpaci, Nilufer Avci, Kezban N Pilanci and 4 more

Abstract read
In one paragraph

Article in Saudi medical journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Asude AksoyDepartment of Medical Oncology, Medical Faculty, Firat University Elazig, Turkey. E-mail. asudeaksoy@hotmail.com.
Hatice Odabas
Serap Kaya
Oktay Bozkurt
Mustafa Degirmenci
Turkan O Topcu
Aydin Aytekin
Erkan Arpaci
Nilufer Avci
Kezban N Pilanci
Havva Y Cinkir
Yakup Bozkaya
Yalcin Cirak
Mahmut Gumus

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo analyze the relationship between clinical features, hormonal receptor status, and survival in patients who were diagnosed with medullary breast cancer (MBC). Methods: Demographic characteristics, histopathological features, and survival statuses of 201 patients diagnosed with MBC between 1995 and 2015 were retrospectively recorded. Survival analyses were conducted with uni- and multivariate cox regression analysis.

resultsMedian follow-up time was 54 (4-272) months. Median patient age at the time of diagnosis was 47 years old (26-90). Of the patients, 91.5% were triple negative. Five-year recurrence free survival time (RFS) rate was 87.4% and overalll survival (OS) rate 95.7%. For RFS, progesterone receptor (PR) negativity, atypical histopathological evaluation, absence of lymphovascular invasion, smaller tumor, lower nodal involvement were found to be favourable prognostic factors by univariate analysis (p less than 0.05). The PR negativity and smaller tumor were found to be favourable factors by univariate analysis (p less than 0.05). However, none of these factors were determined as significant independent prognostic factors for OS (p greater than 0.05).  Conclusion: Turkish MBC patients exhibited good prognosis, which was comparable with survival outcomes achieved in the literature. The PR negativity was related to a better RFS and OS rates.

Indexed as

AdultAgedAged, 80 and overBreastBreast NeoplasmsCarcinoma, MedullaryFemaleHumansMiddle AgedReceptors, EstrogenReceptors, ProgesteroneRetrospective StudiesSurvival AnalysisTurkeyReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID28133688
PMCPMC5329627

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.